March 23, 2008 / 1:10 PM / in 10 years

Canada appeals court backs Pfizer Lipitor patent

NEW YORK (Reuters) - A Canadian appeals court has blocked the sale of a generic form of Pfizer Inc’s PFE.N top-selling cholesterol fighter, Lipitor, by India’s Ranbaxy Laboratories Ltd RANB.BO, overturning a lower court ruling, Pfizer said on Thursday.

The Federal Court of Appeal of Canada issued an order prohibiting approval of Ranbaxy’s product in Canada until a Pfizer patent expires in July 2010, the company said.

The lower court had ruled that the enantiomer, or calcium salt, patent could not block Ranbaxy from seeking approval for a cheaper generic form of the world’s biggest prescription medicine. Lipitor, known generically as atorvastatin calcium, has annual sales of about $12 billion.

Ranbaxy may seek a review of the decision by the Supreme Court of Canada, Pfizer said.

Reporting by Bill Berkrot

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below